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Abstract
The synthesis, material characterization, and in vitro biocompatibility of S-nitrosothiol (RSNO)-
modified xerogels is described. Thiol-functionalized xerogel films were formed by hydrolysis and
co-condensation of 3-mercaptopropyltrimethoxysilane (MPTMS) and methyltrimethoxysilane
(MTMOS) sol-gel precursors at varying concentrations. Subsequent thiol nitrosation via acidified
nitrite produced RSNO-modified xerogels capable of generating nitric oxide (NO) for up to 2 weeks
under physiological conditions. Xerogels also exhibited NO generation upon irradiation with broad-
spectrum light or exposure to copper, with NO fluxes proportional to wattage and concentration,
respectively. Xerogels were capable of storing up to ∼1.31 µmol NO mg−1, and displayed negligible
fragmentation over a 2 week period. Platelet and bacterial adhesion to nitrosated films was reduced
compared to non-nitrosated controls, confirming the antithrombotic and antibacterial properties of
the NO-releasing materials. Fibroblast cell viability was maintained on the xerogel surfaces
illustrating the promise of RSNO-modified xerogels as biomedical device coatings.
1. Introduction
Sustaining a functional interface for indwelling medical devices in their working environment
(e.g., blood, tissue, etc.) remains a significant challenge. Blood-contacting devices such as
stents and intravascular sensors suffer from impaired function due to platelet adhesion and
aggregation [1–3]. Tissue-based devices are sequestered from the surrounding tissue by a dense
collagen capsule due to the foreign body response [4,5]. Isolation of these devices often render
them useless and hinder wound healing. All implanted medical devices also increase the risk
of infection due to bacterial surface contamination. Indeed, indwelling medical devices are
responsible for >1,000,000 hospital acquired infections per year in the U.S. alone [6].
Strategies to actively combat these issues include device coatings that release antithrombotic
or antimicrobial agents (e.g., heparin and silver ions) and have become an important area of
study [7,8]. Surface generation of nitric oxide (NO), a free-radical active in many physiological
processes including platelet activation, angiogenesis, vasodilation, wound healing, and host
defense against infection represents a powerful technique with the potential to alleviate many
of the problems affecting indwelling medical devices today [9–13]. Materials modified with
NO-releasing polymer coatings have proven effective at reducing both bacterial and platelet
adhesion in vitro [14,15], inhibiting in vivo infection [16], and facilitating tissue integration
of the implants [17].
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Due to its reactive nature, NO donors or functional groups that store and release NO have been
widely developed and include nitrosamines, organic nitrates, metal-NO complexes, N-
diazeniumdiolates, and S-nitrosothiols (RSNOs) [18,19]. As compounds that are formed
endogenously via the nitrosation of free thiols by reactive nitrogen species (e.g., N2O3) [20],
RSNOs are a particularly promising class of NO donor for in vivo applications. Endogenous
RSNOs, such as S-nitrosoalbumin and S-nitrosoglutathione (GSNO), act as biological
transporters of NO in the blood stream [11]. As such, concerns regarding the formation of
potentially toxic by-products are minimal compared to other donor systems (e.g., N-
diazeniumdiolates).
Small molecule RSNOs such as S-nitroso-N-acetyl-L-cysteine (SNAC), S-nitroso-N-acetyl-
DL-penicillamine (SNAP), and GSNO have been widely studied as NO delivery agents with
well documented antimicrobial [21] and antithrombotic [22–24] effects. Incorporation of
RSNOs into polymers may extend the utility of these NO donors to applications such as device
coatings, thus providing NO release at a device/tissue (or blood) interface. Despite the potential
benefits of RSNOs, reports of RSNO-modified polymeric coatings for NO generation are
limited. Bohl and West reported the formation of S-nitrosocysteine-modified polyethylene
glycol (PEG) hydrogels capable of generating NO for short periods (4–12 h) [25]. These
polymers reduced smooth muscle cell adhesion on sections of angioplasty-damaged arteries
in rat models [26]. The synthesis of NO-releasing polymers consisting of small molecule
RSNOs such as SNAC and GSNO dispersed in PEG or solid poly(vinyl alcohol)/poly(vinyl
pyrrolidone) films was reported by de Oliveira and co-workers [27–30]. The NO delivery was
accomplished by rapid leaching of the hydrophilic small-molecule RSNO from the polymer
into the soak media. Frost and Meyerhoff described photo-switchable NO-generating materials
via RSNO-modified fumed silica particles doped into silicone rubber polymers [31]. Light was
required to liberate NO from these interfaces (NO fluxes ≥1.7 pmol cm−2 s−1 for nearly 12 h
with 40 W illumination). Seabra et al. reported on polynitrosated polyesters with covalently
attached RSNO functionalities capable of significant initial NO release levels (475 µmol g−1
h−1 for 2 h) at physiological temperature [32]. However, the polyester macromolecules were
water-insoluble liquids best suited for transdermal NO delivery. To date, the above methods
have not been proven useful as coatings for indwelling medical devices due to limited NO
release durations and/or leaching of the NO donor.
Herein, we describe the use of sol-gel chemistry [33] to form RSNO-modified xerogels as
biocompatible NO-releasing coatings. Both the NO release, as a function of multiple NO
release triggers, and the stability of nitrosated 3-mercaptopropyltrimethoxysilane-derived
films are evaluated. The ability of such coatings to resist bacterial and platelet adhesion, and
their effect on fibroblast viability are examined.
2. Materials and Methods
3-Mercaptopropyltrimethoxysilane (MPTMS), ethyltrimethoxysilane (ETMOS), and
isobutyltrimethoxysilane (BTMOS) were purchased from Gelest (Tullytown, PA).
Methyltrimethoxysilane (MTMOS) and diethylenetriamine pentaacetic acid (DTPA) were
purchased from Fluka (Buchs, Switzerland). Pseudomonas aeruginosa (ATCC #19143) was
obtained from American Type Culture Collection (Manassas, VA). Nitric oxide calibration gas
(25.7 ppm; balance N2) was purchased from National Welders Supply Co. (Durham, NC).
Type A19 60 and 100 W General Electric and type A21 200 W Sylvania incandescent light
bulbs were purchased from Lowe’s (Chapel Hill, NC). Whole blood was obtained from healthy
pigs at the Francis Owen Blood Research Laboratory (Chapel Hill, NC). Fetal bovine serum
(FBS), penicillin/streptomycin (P/S) and trypsin were obtained from Sigma (St. Louis, MO).
Eagles minimal essential medium (MEM) was purchased from Gibco (Carlsbad, CA).
Phosphate buffered saline (PBS) used for cell culture experiments was prepared and maintained
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in a sterile environment. L929 mouse fibroblasts (ATCC #CCL-1) were purchased from the
University of North Carolina Tissue Culture Facility (Chapel Hill, NC). The MTT reagent 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and dimethyl sulfoxide
(DMSO) used in the MTT assay were purchased from Fisher Scientific (St. Louis, MO). Other
solvents and chemicals were analytical-reagent grade and used as received. Distilled water was
purified to 18.2 MΩ·cm with a Millipore Milli-Q Gradient A-10 water purification system
(Bedford, MA).
2.1. Xerogel Film Synthesis
Xerogel coatings were prepared as follows. Sols containing 20–80% (v:v total silane) MPTMS
(balance MTMOS) were created by shaking ethanol (800 µL), MTMOS (160–640 µL),
MPTMS (640–160µL; total silane volume = 800 µL), and 0.5 M HCl (25 µl) for 1 h. After
allowing the sols to age under ambient conditions for an additional 4 h, 30 µl aliquots were
cast onto 9 × 25 mm2 precleaned glass substrates. All substrates were sonicated in ethanol for
20 min and dried under N2. Substrates for the 20–60% MPTMS films, were ozone (UV) cleaned
for 20 min in a BioForce TipCleaner (Ames, IA). Substrates for the 80% MPTMS films, were
soaked in 10% (v/v) nitric acid for 30 min at 80 °C, rinsed with distilled water, and dried under
N2. After casting of the sol, all physisorbed films were allowed to dry at room temperature
overnight, and then transferred to a 70 °C oven for 2 d.
2.2. Nitrosothiol Formation
Thiols of MPTMS/MTMOS xerogels were nitrosated by reaction with acidified nitrite [34].
Films were protected from light and incubated for fixed intervals in 0.5 M HCl (2 mL)
containing a 10-fold molar excess of NaNO2 (vs. moles thiol) and 100 µM DTPA. The xerogels
were washed with 100 µM DTPA and stored in the dark at −20 °C until use. Spectral
characterization of RSNO formation was performed by affixing the slides normal to the light
path of a PerkinElmer Lambda 40 UV/Vis Spectrophotometer (Norwalk, CT) in cuvettes
containing 2 mL phosphate buffered saline (PBS; 10mM phosphate, pH 7.4). Characteristic
RSNO absorbance bands (330–350 nm; n0→π* and 550–600 nm; nN→π*) [35,36] were
monitored as a function of nitrosation reaction time and concentration of mercaptosilane in the
xerogel. Resulting spectra were normalized to the corresponding pathlength (i.e., average film
thickness) of each xerogel composition. In addition, each xerogel composition’s absorbance
at 650 nm was baseline subtracted from their respective spectrum to control for background
absorbance of the xerogel.
2.3. Characterization of NO Release
Nitric oxide release from RSNO-modified xerogels was monitored in 1 s intervals using a
Sievers model 280i chemiluminescence nitric oxide analyzer (Boulder, CO). Calibration of the
instrument was performed prior to each experiment using 25.7 ppm NO gas (balance N2) and
air passed through a Sievers NO zero filter. Individual slides were immersed in 25 mL PBS
containing 100 µM DTPA and sparged with a 200 mL/min N2 stream. Temperature was
maintained via a water bath at 0 or 37 °C. Light-initiated NO release was examined by
employing incandescent bulbs of various wattages placed 6 inches above the sample flask.
Copper-initiated release was studied by immersing the slides into 25 mL solutions of 10 and
25 µM CuBr2 in PBS. The sample flask was shielded from light with aluminum foil when light
was not the intended initiator of NO release.
2.4. Xerogel Film Stability
Nitrosated xerogel films on glass slides (n = 5) were immersed in 10 mL PBS and incubated
at 37 °C. Films were removed and transferred to fresh solutions of PBS at fixed intervals.
Silicon (Si) concentrations in the PBS soak solutions were determined using a direct current
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plasma optical emission spectrometer (DCP-OES; ARL-Fisons Spectraspan 7; Beverly, MA)
calibrated with 0–50 ppm Si standard solutions in PBS.
2.5. Contact Angle Measurements
Static water contact angle measurements of control and RSNO-modified xerogels were
acquired with a KSV Instruments Cam 200 Optical Contact Angle Meter (Helsinki, Finland).
2.6. Film Thickness Measurements
Film thickness of the RSNO-modified xerogels was measured with a Tencor Alpha-Step 200
Profilometer (San Jose, CA). Half of the RSNO-modified xerogel coating was removed from
the glass substrate and the interface was probed to acquire the film thickness.
2.7. Bacterial Adhesion to RSNO Xerogels
P. aeruginosa was cultured at 37 ºC in tryptic soy broth (TSB), pelleted by centrifugation,
resuspended in 15% glycerol (v:v in PBS), and stored at −80 ºC. Cultures for bacterial adhesion
studies were grown from a −80 ºC stock in 37 ºC TSB overnight. A 1 mL aliquot of overnight
culture was inoculated into 100 mL fresh TSB, incubated at 37 ºC with rotation, and grown to
a concentration of ∼108 colony-forming units (cfu)/mL (verified by 10-fold serial dilutions in
PBS, plating on tryptic soy agar nutrient plates, and subsequent cfu enumeration). The bacteria
were pelleted by centrifugation, rinsed with ultrapure water, and resuspended in sterile PBS.
Control and RSNO-modified xerogels were immersed in 4-mL aliquots of bacterial suspension
and incubated at 37 ºC. After 1 h, the xerogel substrates were removed from the bacterial
suspension, gently immersed in ultrapure water to remove loosely-adhered cells, and dried
under a stream of N2. To quantify bacterial adhesion, substrates were imaged in phase-contrast
mode using a Zeiss Axiovert 200 inverted optical microscope (Chester, VA) at 20x
magnification. Digital micrographs were captured with a Zeiss Axiocam digital camera
(Chester, VA). To determine the percent surface coverage of bacteria, each image was digitally
processed by applying a threshold value to differentiate adhered cells from the background.
The number of pixels corresponding to adhered bacterial cells was digitally enumerated and
the extent of bacterial adhesion reported as the percent of the xerogel substrate surface covered
with bacterial cells.
2.8. Platelet Adhesion to RSNO Xerogels
Porcine blood from healthy pigs was drawn into acid citrate dextrose (ACD) anticoagulant (1
part ACD to 9 parts whole blood). Within 30 min of collection, samples were centrifuged at
200 g for 30 min at room temperature to obtain platelet rich plasma (PRP). To restore normal
platelet activity, calcium chloride (CaCl2) was added to the PRP supernatant to a final
concentration of 0.5 mM Ca2+ while incubating the PRP for 5 min at 37 ºC [37]. For platelet
adhesion studies, control and RSNO-modified xerogels were immersed in PRP for 1 hr at 37
ºC. The slides were then dip-rinsed in Tyrode’s buffer (137 mM NaCl, 2.7 mM KCl, 5.6 mM
glucose, 3.3 mM KH2PO4, pH 7.35) to remove loosely adhered platelets and immersed in 1%
glutaraldehyde (v/v, Tyrode’s buffer) to fix adherent cells. To preserve cell morphology, the
slides were rinsed with Tyrode’s buffer and Milli-Q purified water and then chemically dried
by immersion in 50%, 75%, and 95% ethanol (v/v, balance water) for 5 min, 100% ethanol for
10 min, and hexamethyldisilazane overnight [38]. After solvent evaporation, films were
sputtered with an Au/Pd alloy and examined for platelet adhesion and morphology using a
Hitachi S-4700 scanning electron microscope (SEM) at a working distance of 12 mm and a
magnification of 1100x. Activated platelets were defined as exhibiting a dendritic or fully
spread morphology. The number of adhered activated platelets was physically counted from
the images.
Riccio et al. Page 4













2.9. Fibroblast Viability on RSNO-Modified Xerogels
L929 mouse fibroblasts were grown to subconfluency in media (MEM with 10% FBS, 20 U/
mL penicillin and 20 µg/mL streptomycin) at 37 °C and 5% CO2. Cells were then trypsinized
and resuspended in media at a concentration of 2 × 105 cells/mL. Xerogels were cast in 96-
well microplates, nitrosated via acidified nitrite, and rinsed thrice with sterile 100 µM DTPA.
Control and RSNO-modified xerogels were then incubated for 24 h with the fibroblast
suspension (200 µL per well) at 37 °C and 5% CO2. After 24 h, a MTT viability assay was
carried out [39]. Briefly, 40 µL of a 1 mg/mL MTT solution in sterile PBS was added to each
well and incubated for 3 h, after which all solution was removed from the well and 100 µL
DMSO was added to solubilize remaining crystals. The solution was then removed from the
wells and added to fresh plates before analysis. In this way the absorbance measured at 570
nm was proportional to the concentration of viable cells in each well and not affected by any
absorbance from the xerogel. Fibroblast viability on RSNO-modified and control xerogels was
reported relative to the viability of fibroblasts on uncoated polystyrene wells at 24 h. Data are
expressed as mean value ± standard deviation (n ≥ 8). Statistical significance was tested using
a single factor ANOVA test (α = 0.05).
3. Results and Discussion
3.1. Xerogel Synthesis and Characterization
The relative ease of xerogel modification using alkoxysilane and organosilane precursors
makes sol-gel chemistry a convenient scaffold to prepare and fabricate NO-releasing materials
and devices [40]. In these experiments, 3-mercaptopropyltrimethoxysilane (MPTMS), a
commercially available thiol-terminated alkoxysilane, was hydrolyzed and co-condensed with
one of three backbone alkylalkoxysilanes: methyltrimethoxysilane (MTMOS),
ethyltrimethoxysilane (ETMOS), and isobutyltrimethoxysilane (BTMOS). Covalent
incorporation of alkylalkoxysilanes into the siloxane network as inert polymer backbone
materials facilitates control over the NO flux generated by the material and enhances xerogel
stability [41]. While all sols appeared to form homogenous gels, curing of xerogel films formed
with the bulky ETMOS and BTMOS alkylalkoxysilanes required prohibitively long periods,
most likely due to the decreased rates of hydrolysis of sterically hindered alkoxysilanes [33].
After overnight aging of the sol, films cast from these materials and stored in a 70 °C oven for
>2 weeks remained viscous and tacky. Conversely, films of MPTMS/MTMOS sols aged 4 h
solidified overnight under ambient conditions, forming clear, rigid films when dried for 2 d at
70 °C. Methyltrimethoxysilane was thus selected as the backbone alkoxysilane in all further
experiments. Sols synthesized with ≥80% MPTMS exhibited uneven coating of glass
substrates, which led to irreproducible surface areas. To remedy this, glass slides were soaked
in a 10% (v:v) nitric acid solution at 80 °C for 30 min prior to coating to promote siloxane
formation between the silanes and silanols inherent to the glass surface, thus enhancing
adsorption of the coating with the possibility of covalent bond formation.
Indeed, the acid treatment led to uniform and reproducible 80% MPTMS xerogel coatings.
Films formed with 100% did not uniformly coat the glass even with nitric acid treatment. The
thickness of each composition of resulting xerogel was measured using profilometry. Upon
increasing the MPTMS concentration from 20–80% (v:v total silane, balance MTMOS), the
average thickness increased from 14.22 ± 2.64 to 35.01 ± 8.62 µm. Resulting xerogels were
weighed and found to have average masses of 10.33 ± 0.61, 11.37 ± 0.55, 13.90 ± 0.70, and
10.63 ± 0.68 mg for 20, 40, 60, and 80% MPTMS compositions, respectively. Although masses
were relatively constant for all xerogels formed, the relative thicknesses increased with larger
amounts of MPTMS. Xerogels with greater MTMOS character formed thinner films due to
closer packing of the methyl group compared to the bulkier mercaptopropyl group.
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To establish conditions for optimal RSNO formation in the xerogel, films were prepared using
20–80% (v:v) MPTMS (balance MTMOS). Nitrosation of the primary thiol of MPTMS was
carried out by immersing cured xerogel films in a solution of acidified nitrite containing 100
µM DTPA to reduce catalytic RSNO decomposition by adventitious copper ions. Reaction of
the pendant thiols of the xerogel network with nitrous acid resulted in S-nitrosothiol formation
(Eq. 1) [36] with a concomitant color shift of the transparent xerogel film to a deep pink hue.
(1)
The characteristic UV and visible absorbance maxima of the S-NO bond (at 336 and 545 nm,
respectively) were monitored as a measure of the extent of thiol nitrosation. After 3 h immersion
in acidified nitrite, no further absorbance increases in the films were observed, indicating
maximal RSNO formation (data not shown). Extended soaking periods up to 24 h resulted in
a slight overall decrease in measured absorbance, which was attributed to partial thermal
decomposition of the RSNOs. As shown in Figure 1, increasing the concentration of MPTMS
in the xerogel films resulted in an increased overall absorbance after nitrosation. The observed
pink color was also darker indicating greater RSNO formation for the more heavily thiol-
functionalized films. The color shift associated with nitrosation is thus a useful indication of
the concentration of RSNOs (and hence NO-release potential) in the xerogel films.
The long-term stability of RSNO-modified xerogels in 37 °C PBS solution was monitored by
monitoring siloxane network degradation via elemental analysis of Si in PBS soak solutions.
The xerogels films were stable in PBS. Solution in which 20–80% MPTMS/MTMOS films
had been soaked for 2 weeks showed negligible levels of xerogel fragmentation (<0.5 ppm).
In fact, the Si in the xerogel soak solutions was reduced compared to controls containing only
bare glass substrates, ostensibly due to masking of ∼50% of the glass surface by the xerogel
films.
3.2. NO-Release Characterization of RSNO-Modified Xerogels
S-Nitrosothiols exhibit a multitude of decomposition triggers [36]. Irradiation of RSNOs at
either of their two absorption maxima (i.e., 330–350 and 550–600 nm) results in homolytic
cleavage of the S–N bond and generation of NO and a thiyl radical. The thiyl radical can trigger
NO release via reaction with an additional RSNO molecule to produce a second equivalent of
NO and the corresponding disulfide [36].
Photo-initiated NO-release from RSNO-modified xerogels was measured via
chemiluminesence as a real-time flux from individual films immersed in 100 µM DTPA (pH
7.4 PBS). The xerogels were irradiated using broadband, white light of varying intensity while
the temperature of the sample flask was maintained at 0 °C to distinguish photo-initiation from
thermal NO release. Films exhibited a characteristic on/off behavior of NO production when
either irradiated by light or enclosed in the dark, respectively (Fig. 2A). Xerogels were also
found to have pronounced increases in NO flux upon exposure to higher light intensities (Fig.
2B). Of note, the inset of Figure 2B details the flux of an RSNO-modified xerogel without the
presence of light and at 0 °C. Although the thermal decomposition is hindered, it is still
observed at 0 °C as demonstrated by a non-zero baseline in Figure 2A when the film was
shielded from light.
The rapid kinetics of NO release from these films in the presence of a 200 W light source
indicates that photo-initiation is an efficient means to quantify the amount of NO stored in the
xerogel network. To determine the total NO storage capacity of the xerogels, films were
irradiated with a 200 W light for periods of 16 h. The total amount of stored NO scaled
proportionally with the amount of incorporated MPTMS in the xerogels, ranging from 0.47 ±
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0.13 to 1.31 ± 0.07 µmol mg−1 (Table 1). Films examined after exposure to the light for 16 h
lacked any remaining pinkish hue, providing a visual indication that all stored NO had indeed
been released, as corroborated by a return to baseline on the chemiluminescent NO analyzer.
Catalytic reaction of RSNOs with Cu(I), commonly generated from the reduction of added or
adventitious Cu(II) via trace thiolate ion, results in NO production [42]. Thus, the use of copper
as a trigger to generate NO from RSNOs has been reported on extensively in the literature
[18,36,43]. The extent of copper-induced NO generation from RSNO-modified xerogels was
examined by immersing xerogel films in various concentrations of copper bromide. Assays
were performed with the Cu(II) compound opposed to Cu(I) because of the general water-
insolubility of Cu(I) compounds [44]. As shown in Figure 3, xerogels exhibited a NO flux
dependance on copper concentration with the greatest NO flux (∼26 pmol cm−2 s−1) observed
at 25 µM CuBr2, the largest concentration that we investigated. Since most copper in the body
is bound to proteins and peptides for transport and homeostasis [44], the relevance of this
concentration remains questionable. The concentration of “free” copper, or loosely bound
hydrated Cu(I) and Cu(II) complexes, in serum is approximately 1.6 µM [45] and less than a
single atom per cell intracellularly [46,47]. Dicks and Williams reported that Cu(II) complexed
to amino acids, tripeptides, human serum albumin, and ceruloplasmin decomposes RSNOs to
generate NO upon reduction to Cu(I), indicating a potential for copper-initiated NO release in
vivo [48]. However, the same authors concluded that although the tightly bound forms of Cu
(II) can generate NO from RSNOs, the NO release kinetics are decreased when compared to
that initiated by “free” copper. Unfortunately, a model for elucidating plausible physiological
NO fluxes due to copper-initiated RSNO decomposition remains incomplete.
Thermal RSNO decomposition represents the most plausible trigger of NO release from
RSNO-modified xerogels employed as biomedical implant coatings. To model this pathway,
xerogel films were immersed in 25 mL of 100 µM DTPA (pH 7.4 PBS), maintained at 37 °C,
and shielded from ambient light. As shown in Figure 4, NO fluxes were monitored for 2 weeks
under these conditions. Although the amount of MPTMS in each film differed, all xerogels
exhibited similar initial fluxes of NO at 37 °C. Experiments are currently underway to probe
this behavior further. After the initial maximum flux of NO subsided, the xerogels exhibited
NO fluxes dependant on their MPTMS concentrations (Fig. 4A). After 24 h, the NO fluxes of
all films dropped significantly lower, but remained measurable up to 2 weeks (Fig. 4B).
Previous work has deduced that a NO flux of 0.4 pmol cm−2 s−1 is necessary to reduce platelet
adhesion to surfaces [49]. The 20% MPTMS xerogel demonstrated a flux above this threshold
for up to 3 d, while the 40–80% MPTMS xerogel compositions released at or above this level
for periods of up to 1–2 weeks. Likewise, NO fluxes >35 pmol cm−2 s−1 have been reported
to reduce P. aeruginosa adhesion to surfaces [50]. RSNO-modified xerogels exhibited initial
maximum NO fluxes of ∼600 pmol cm−2 s−1, an order of magnitude larger than the reported
threshold and thus large enough to resist bacterial adhesion during the critical phase soon after
device implantation [7]. Hetrick et al. also reported that the delivery of 1.35 µmol of NO per
cm2 of implant surface area reduced the thickness of collagen encapsulation at the site of a
subcutaneous implant by ≥50% compared to controls [17]. Each of the RSNO-modified xerogel
compositions reported herein was capable of storing at least 2.35 µmol cm−2, well in excess
of that required to reduce encapsulation in vivo. The total amount of NO stored coupled with
physiologically relevant fluxes, highlight RSNO-modified xerogels as candidate coatings for
improving the biocompatibility of indwelling medical devices. Further studies focusing on the
anti-bacterial and anti-platelet properties of the xerogels were thus conducted.
3.3. Antibacterial Properties of RSNO-Modified Xerogels
To assess the antibacterial properties of RSNO-modified xerogel films, controls and NO-
releasing substrates were incubated for 1 h in a suspension of P. aeruginosa (108 CFU/mL) in
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PBS. After removal from the bacterial suspension, the extent of bacterial adhesion to substrates
was determined using phase contrast optical microscopy. As shown in Figure 5, a significant
reduction in bacterial adhesion was observed at NO-releasing xerogels compared to controls,
an observation consistent with the findings of previous studies [14,50–53]. Specifically, P.
aeruginosa adhesion was reduced by 73, 79, 77, and 93% at RSNO-modified 20, 40, 60, and
80% MPTMS/MTMOS xerogels, respectively, compared to controls with identical
mercaptosilane content. From a clinical perspective, these results are promising as the reduction
of initial bacterial adhesion is often regarded as the most critical step for preventing infection
related to indwelling medical devices [7,54,55]. It is also likely that the continued NO release
from RSNO-modified xerogels may exert beneficial long-term antibacterial and wound-
healing properties in vivo [16]. Studies to assess the antibacterial properties of RSNO-modified
xerogels in an animal model are currently underway.
As shown in Figure 5, bacterial adhesion to controls (non-nitrosated xerogels) decreased with
increasing thiol concentration. Indeed, a 38% reduction in P. aeruginosa surface coverage was
observed for controls as the thiol concentration within the xerogel increased from 20 to 80%
(v:v). Previous work suggests that such reduced bacterial adhesion may be the result of altered
surface hydrophilicity and the hydrophobic effect known to mediate bacterial adhesion [56–
58]. To understand the influence of thiol concentration on surface hydrophobicity, static water
contact angles were measured at both nitrosated and control xerogels. As shown in Table 2,
the water contact angle of control xerogels decreased from 77 to 48° as the concentration of
MPTMS within the xerogel was increased from 20 to 80% (v:v total silane, balance MTMOS).
Analogous behavior was observed for RSNO-modified xerogels indicating that more
hydrophilic surfaces are formed with increasing thiol concentration for both control and RSNO-
modified MPTMS/MTMOS xerogels, likely resulting in reduced hydrophobic interaction
between bacterial cells and the surface. Of note, the water contact angle of nitrosated xerogels
was consistently lower (i.e., more hydrophilic) than non-nitrosated controls of the same thiol
concentration. However, this difference in surface hydrophobicity alone does not account for
the full reduction in bacterial adhesion. For example, the contact angle of both control 60%
MPTMS and NO-releasing 40% MPTMS was 58°. However, 30% bacterial surface coverage
was observed at control 60% MPTMS, while the surface coverage at NO-releasing 40%
MPTMS xerogels was only 8%. While both surfaces were characterized by identical water
contact angles, the NO-releasing surface had 73% less bacterial adhesion, indicating that it is
primarily NO release (and not surface hydrophobicity) that dictates the extent of bacterial
adhesion to these materials.
3.4. Antithrombotic Properties of RSNO-Modified Xerogels
The degree of activation of surface-adhered platelets is crucial in determining the
hemocompatibility of a material [59]. As platelets become activated, morphological changes
occur shifting the geometry of a platelet from a native discoid shape to dendritic (i.e., exhibiting
pseudopodia) and ultimately fully spread conformations [60]. The effect of RSNO-modified
xerogels on platelet activation and adhesion was examined by exposing 20–80% MPTMS
xerogel films to platelet-rich porcine plasma for 1 h. Scanning electron microscopy (SEM) was
used to probe the morphological state of adhered platelets. Table 3 illustrates the observed
reductions of activated platelets at RSNO-modified surfaces compared to control xerogels.
Representative SEM micrographs of platelet adhesion to xerogel surfaces are shown in Figure
6. The NO-release decreased the average activated platelet coverage on RSNO-modified films
versus controls, as determined from the mean number of activated platelets. Although all
compositions showed a reduction in the average number of activated adhered platelets versus
corresponding controls, the 40 and 60% MPTMS NO-releasing films were the only ones to
exhibit statistically significant decreases (47 and 52%, respectively) (P ≤ 0.05). The platelet
activation for 20% MPTMS NO-releasing xerogels may be attributed to a lower NO flux
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generated by these materials (≤ 30 pmol cm−2 s−1 after 30 min). The increased adhesion of
activated platelets to 80% MPTMS NO-releasing xerogels versus NO-releasing xerogels with
lower MPTMS concentration (i.e., 20–60%) is attributed to the increased surface roughness of
this composition, as evident in Figure 6. [61]. In vivo, minimum NO flux requirements are
likely to increase due to rapid NO scavenging by other free radicals, thiols, and heme proteins
in blood [62]. Nevertheless, the low thrombogenicity and extended NO-release durations for
RSNO-modified xerogel coatings support the further investigation of these materials as
thromboresistant coatings.
3.5. Fibroblast Viability on RSNO-Modified Xerogels
The methylthiazol tetrazolium (MTT) assay was employed to determine the general
cytotoxicity of RSNO-modified xerogels to mammalian cells. The MTT assay is a quantitative
colorimetric assay that measures the concentration of viable cells through the cleavage of a
tetrazolium ring in active mitochondria, resulting in the production of a formazan that absorbs
in solution at 570 nm [39]. Since the reaction occurs only in living cells, the optical density
measured is directly related to the concentration of viable cells. The viability of L929 mouse
fibroblasts on control and RSNO-modified 20–80% MPTMS/MTMOS xerogels was compared
to fibroblast viability on uncoated, sterile polystyrene (PS) wells (Fig. 7). Relative to uncoated
PS wells, the fibroblast viability on control (non-nitrosated) xerogel surfaces after 24 h was
61.8–80.1%. The reduced viability may be attributed to decreased cell adhesion on the
hydrophilic thiol-terminated surfaces. As shown in Figure 7, the fibroblast viability was slightly
less for the nitrosated (RSNO-modified) xerogels. At 24 h, the relative viability was 42.0–
58.6% that of PS for the NO-releasing xerogels. The initial decrease in fibroblast viability at
RSNO-modified xerogels compared to controls coincides with the initial burst of NO released
from the surface. Although NO’s toxicity at elevated concentrations is well documented [63],
given the anti-adhesion properties of RSNO-modified xerogels towards bacteria and platelets,
it is possible NO release may prevent fibroblast adhesion to the xerogel surface, contributing
to the decrease in viability observed.
Of note, the fibroblast viability at both the RSNO-modified and control 80% MPTMS/MTMOS
xerogel surfaces was different than that observed for other MPTMS concentrations. When the
80% MPTMS xerogels were cast in the bottom of the PS 96-well plates, the sols did not appear
to wet the surfaces as completely or uniformly as the other MPTMS compositions. Unlike the
glass substrates, treatment with nitric acid did not remedy this problem. Such a drastic increase
in viability at 80% MPTMS/MTMOS xerogels would be expected if a significant portion of
the PS surface was left available for fibroblast adhesion. As the coating of certain medical
devices is the intended application of these biomaterials, future work is planned to explore and
optimize the adherence of the xerogel coatings to a range of medical-grade polymeric materials.
Experiments to elucidate the effect of NO on fibroblast viability and adhesion in a dose
dependent manner are also currently in progress.
4. Conclusions
Poor biocompatibility continues to plague many indwelling medical devices. Nitric oxide
release at the device/tissue (or blood) interface has been shown to help overcome this problem
via the reduction of platelet adhesion and activation, bacterial adhesion, and the foreign body
response. We have developed S-nitrosothiol (RSNO)-modified xerogels as versatile NO-
releasing coatings. Such NO-releasing coatings may mitigate toxicity concerns due to the
endogenous nature of S-nitrosothiols and thus a decomposition pathway that mimics
biologically-occurring processes. Nitric oxide levels ranging from 0.47. ± 0.13 to 1.31 ± 0.07
µmol mg−1 may be stored with tunable NO release via exposure to light, copper, and/or heat.
Of relevance to future biomedical device applications, the materials were stable under
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physiologically-relevant conditions and released NO above previously determined threshholds
required to reduce platelet and bacterial adhesion at surfaces for periods up to 2 weeks.
Pronounced reduction in P. aeruginosa and activated platelet adhesion was observed for the
RSNO-modified xerogels versus controls. Fibroblasts exposed to RSNO-modified xerogels
remained viable, further suggesting the potential biomedical use of such coatings. Future in
vivo studies will explore how these materials fare with regards to bacterial infection and wound
healing.
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Absorbance spectra of RSNO-modified xerogels comprised of (—) 20% MPTMS; (--) 40%
MPTMS; (···) 60% MPTMS; and (-·-) 80% MPTMS (v:v total silane, balance MTMOS).
Baseline subtracted spectra were normalized to the average pathlength (film thickness) of each
respective film.
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(A) On/off NO release behavior of RSNO-modified 20% MPTMS (v:v total silane, balance
MTMOS) xerogel as a function of light irradiation (60 W light source at 0 °C).
(B) Nitric oxide flux from RSNO-modified 80% MPTMS (v:v total silane, balance MTMOS)
xerogels irradiated with 0, 60,100, and 200 W at 0 °C. [Inset: Enlarged view of NO flux without
irradiation]
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Nitric oxide flux from RSNO-modified 20% MPTMS (v:v total silane, balance MTMOS) films
in 0, 10, and 25 µM CuBr2 / PBS solution at 0 °C. (Note: 0 µM CuBr2 is 100 µM DTPA (pH
7.4 PBS))
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Nitric oxide flux from RSNO-modified xerogels in 37 °C 100 µM DTPA (pH 7.4 PBS). Data
points correspond to the average of 3 films incorporating (Δ) 80%; (▴) 60%; (□) 40% and (■)
20% MPTMS (v:v total silane, balance MTMOS). (A) Initial NO flux during the first 30 min
of immersion. (B) Nitric oxide flux from 1–14 d. [Inset: Enlarged view of 5–14 d NO release.]
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P. aeruginosa adhesion to control (dark) and RSNO-modified (light gray) MPTMS/MTMOS
xerogels. Bacterial adhesion reported as percent surface coverage.
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Representative scanning electron microscopy (SEM) images of platelet adhesion to (A,C,E,G)
control and (B,D,F,H) RSNO-modified xerogels. 3-Mercaptopropyltrimethoxysilane (v:v total
silane, balance MTMOS) xerogel compositions: (A,B) 20%, (C,D) 40%, (E,F) 60%, and (G,H)
80%. Note the enhanced surface roughness of the 80% composition (G,H).
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Viability of L929 Mouse fibroblast cells on polystyrene tissue culture wells (PS), control
(dark), and RSNO-modified (light gray) MPTMS/MTMOS xerogels after 24 h. Polystyrene
tissue culture wells were either untreated (dark) or exposed to nitrosating conditions (light
gray).
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Table 1
Total NO stored in RSNO-modified MPTMS/MTMOS xerogels
% MPTMSa Total NO released (µmol mg−1)b
20 0.47 ± 0.13
40 0.68 ± 0.07
60 0.81 ± 0.03
80 1.31 ± 0.07
a
Balance MTMOS, (v:v total silane)
b
Average from n=3, normalized to average mass of resulting xerogel
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Table 2
Contact angles of control and RSNO-modified MPTMS/MTMOS xerogels
Contact angle (deg)b
% MPTMSa control RSNO-modified
20 77 ± 1 67 ± 3
40 73 ± 2 58 ± 2
60 58 ± 3 51 ± 1
80 48 ± 2 44 ± 4
a
Balance MTMOS, (v:v total silane)
b
Sessile drop method, H2O. Average from n=3
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Table 3
Amount of activated platelets adhered to control and RSNO-modified MPTMS/MTMOS xerogels.
Adhered activatedb plateletsc
% MPTMSa control RSNO-modified
20 129 ± 62 106 ± 17
40 210 ± 6 111 ± 4
60 163 ± 49 79 ± 8
80 205 ± 64 149 ± 8
a
Balance MTMOS, (v:v total silane)
b
Defined as dendritic or fully spread morphology
c
Aqcuired from SEM images. Average from n ≥ 3
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